Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
- DOI
- 10.1097/mpa.0000000000000113
- Published
- 2014 May
- Container
- Pancreas
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/mpa.0000000000000113,
title = {Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.},
author = {Delpassand ES and Samarghandi A and Zamanian S and Wolin EM and Hamiditabar M and Espenan GD and Erion JL and O'Dorisio TM and Kvols LK and Simon J and Wolfangel R and Camp A and Krenning EP and Mojtahedi A},
year = {2014},
journal = {Pancreas},
doi = {10.1097/mpa.0000000000000113},
url = {https://doi.org/10.1097/mpa.0000000000000113}
}RIS
TY - JOUR TI - Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. AU - Delpassand ES AU - Samarghandi A AU - Zamanian S AU - Wolin EM AU - Hamiditabar M AU - Espenan GD AU - Erion JL AU - O'Dorisio TM AU - Kvols LK AU - Simon J AU - Wolfangel R AU - Camp A AU - Krenning EP AU - Mojtahedi A PY - 2014 JO - Pancreas DO - 10.1097/mpa.0000000000000113 UR - https://doi.org/10.1097/mpa.0000000000000113 ER -
APA
ES, D., A, S., S, Z., EM, W., M, H., GD, E., JL, E., TM, O., LK, K., J, S., R, W., A, C., EP, K., & A, M. (2014). Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.. Pancreas. https://doi.org/10.1097/mpa.0000000000000113
Source records
- pubmed · retrieved 2026-09-27T12:10:59.593Z
- europe-pmc · retrieved 2026-09-27T12:10:59.618Z